|  |
| --- |
| **Supplementary Table S3.** Correlation between HOXB9 expression and clinico-pathologic characteristic in bevacizumab treated colorectal cancer patients |
| **Characteristic** | **HOXB9 negative n = 14 (24.14%)** | **HOXB9 positive n = 44 (72.86%)** | ***P*** |
| **Age** |  |  | 0.55 |
| <69 years | 7 | 26 |  |
| >69 years | 7 | 18 |  |
| **Primary tumor size (T)** |  |  | 0.584 |
| T1-2 | 2 | 9 |  |
| T3-4 | 12 | 34 |  |
| **PS ECOG** |  |  | 0.453 |
| PS 0 | 10 | 29 |  |
| PS 1-2 | 3 | 15 |  |
| **Time of metastasis occurrence** |  |  | 0.663 |
| Metachronous | 6 | 16 |  |
| Synchronous | 8 | 28 |  |
| **Mutational status** |  |  | 0.187 |
| B-RAF/N-RAS Wild-type | 14 | 39 |  |
| B-RAF/N-RAS Mutated | 0 | 5 |  |
| **Liver metastasis** |  |  | 0.061 |
| No | 8 | 13 |  |
| Yes | 6 | 31 |  |
| **KRAS status** |  |  | 0.702 |
| Wild-type | 4 | 15 |  |
| Mutated | 10 | 29 |   |
|  |  |  |  |